Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report)‘s stock had its “sell (e+)” rating reissued by equities research analysts at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.
Ernexa Therapeutics Trading Up 6.0%
Shares of ERNA stock opened at $1.24 on Friday. The company has a market capitalization of $9.51 million, a P/E ratio of -0.02 and a beta of 5.62. The business’s 50 day moving average is $1.29 and its two-hundred day moving average is $2.08. Ernexa Therapeutics has a 12-month low of $1.09 and a 12-month high of $18.75.
Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.61) earnings per share (EPS) for the quarter.
About Ernexa Therapeutics
Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.
Featured Stories
- Five stocks we like better than Ernexa Therapeutics
- What Are Dividend Challengers?
- PulteGroup Is Down But Not Out—Here’s What Wall Street Missed
- Insider Buying Explained: What Investors Need to Know
- Cleveland-Cliffs Breaks to New Highs on Earnings, More Upside?
- What Makes a Stock a Good Dividend Stock?
- Is Landstar the Next Big Winner in Transportation Stocks?
Receive News & Ratings for Ernexa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ernexa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
